Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts

[1]  F. Balloux,et al.  Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2 infection , 2021, medRxiv.

[2]  P. Freemont,et al.  Optimized protocol for a quantitative SARS-CoV-2 duplex RT-qPCR assay with internal human sample sufficiency control , 2021, Journal of Virological Methods.

[3]  H. Rammensee,et al.  Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups , 2021, Vaccines.

[4]  S. Kent,et al.  CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity , 2021, Immunity.

[5]  C. Szeto,et al.  CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses , 2021, Immunity.

[6]  D. Rader,et al.  Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection , 2021, Cell.

[7]  Gavin J. D. Smith,et al.  Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients , 2021, Cell Reports.

[8]  R. Tedder,et al.  Detection and Quantification of Antibody to SARS-CoV-2 Receptor Binding Domain Provides Enhanced Sensitivity, Specificity and Utility , 2021, SSRN Electronic Journal.

[9]  A. Tanuri,et al.  Genomic Characterization of a Novel SARS-CoV-2 Lineage from Rio de Janeiro, Brazil , 2020, Journal of Virology.

[10]  Leo Swadling,et al.  Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection , 2020, Science Immunology.

[11]  J. Bloom,et al.  A human coronavirus evolves antigenically to escape antibody immunity , 2020, bioRxiv.

[12]  M. Vetter,et al.  Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19 , 2020, Journal of Clinical Virology.

[13]  B. Bosch,et al.  Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63 , 2020, Scientific Reports.

[14]  P. Rosenstiel,et al.  Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19 , 2020, Immunity.

[15]  Sagar,et al.  Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells , 2020, Nature Medicine.

[16]  Chloe H. Lee,et al.  Potential CD8+ T Cell Cross-Reactivity Against SARS-CoV-2 Conferred by Other Coronavirus Strains , 2020, Frontiers in Immunology.

[17]  A. Charlett,et al.  SARS-CoV-2 responsive T cell numbers are associated with protection from COVID-19: A prospective cohort study in keyworkers , 2020, medRxiv.

[18]  G. MacBeath,et al.  Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein , 2020, Immunity.

[19]  D. Nickle,et al.  Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection , 2020, Science.

[20]  H. Rammensee,et al.  SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition , 2020, Nature immunology.

[21]  P. Klenerman,et al.  T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses , 2020, Nature Communications.

[22]  N. Hacohen,et al.  Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity , 2020, Science.

[23]  P. Sopp,et al.  Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 , 2020, Nature Immunology.

[24]  S. Mallal,et al.  Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans , 2020, Science.

[25]  Martin Linster,et al.  SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.

[26]  A. Sette,et al.  Pre-existing immunity to SARS-CoV-2: the knowns and unknowns , 2020, Nature Reviews Immunology.

[27]  Morten Nielsen,et al.  Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.

[28]  U. Qimron.  Faculty Opinions recommendation of Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[29]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[30]  Christopher Earl,et al.  Preexisting and de novo humoral immunity to SARS-CoV-2 in humans , 2020, Science.

[31]  U. Reimer,et al.  Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors , 2020, medRxiv.

[32]  A. Monto,et al.  Coronavirus Occurrence and Transmission Over 8 Years in the HIVE Cohort of Households in Michigan , 2020, The Journal of infectious diseases.

[33]  A. Sanchez‐Mazas,et al.  The HLA-net GENE[RATE] pipeline for effective HLA data analysis and its application to 145 population samples from Europe and neighbouring areas. , 2014, Tissue antigens.

[34]  Jonathan J Deeks,et al.  Cellular immune correlates of protection against symptomatic pandemic influenza , 2013, Nature Medicine.

[35]  S. Swain,et al.  Accumulation of NFAT mediates IL-2 expression in memory, but not naïve, CD4+ T cells , 2007, Proceedings of the National Academy of Sciences.

[36]  P. Klenerman,et al.  Dynamic Relationship between IFN-γ and IL-2 Profile of Mycobacterium tuberculosis-Specific T Cells and Antigen Load1 , 2007, The Journal of Immunology.

[37]  G. Davies,et al.  Knowns and Unknowns , 2003 .

[38]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.